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To identify novel non-invasive biomarkers for improved detection, risk assessment 
and prognostic evaluation of cancer, expression profiles of circulating microRNAs 
are currently under evaluation. Circulating microRNAs are highly promising 
candidates in this context, as they present some key characteristics for cancer 
biomarkers: they are tissue-specific with reproducible expression and consistency 
among individuals from the same species, they are potentially derived directly from 
the tumor and therefore might correlate with tumor progression and recurrence, and 
they are bound to proteins or contained in sub-cellular particles such as 
microvesicles or exosomes, making them highly stable and resistant to degradation. 
This review highlights the origin of circulating microRNAs, their stability in blood 
samples, and techniques to isolate exosomal microRNAs, and then addresses the 
current evidence supporting potential clinical applications for circulating miRNAs for 
diagnostic and prognostic purposes.  
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The identification and validation of biomarkers that can be measured routinely in 
easily accessible samples, and that are able to diagnose cancer, predict treatment 
efficacy, and the risk of progression or relapse, is a major challenge in cancer 
research. In recent years, much work has focussed on a novel class of molecules 
that are promising candidates in this context: MicroRNAs (miRNAs, miRs). MiRNAs 
are a well-known class of regulatory molecules, which control translation and stability 
of messenger RNA (mRNA) post-transcriptionally. It is postulated that one single 
miRNA can regulate the expression of mRNA from up to hunderds of gene [1]. Since 
the first release of miRBase (a database that overviews all known miRNAs) in 2002, 
the number of miRNA loci has increased constantly, with 24521 miRNAs identified in 
206 species in 2013 [2]. Interestingly, a considerable number of these miRNAs map 
to regions of the human genome that are known to be altered in cancer [3]. Esquela-
Kerschner et al. established the term „oncomirs“ for miRNAs with oncogenic function, 
implying that abnormalities in miRNA expression might either directly result in de-
differentiation of cells allowing tumor formation to occur [4], or that on the other hand 
alterations of miRNA expression could be used for tumor classification, diagnosis and 
prognosis in cancer.  
 
Most early studies investigated miRNA expression patterns in fresh frozen samples 
such as tumor biopsies or resection specimens, or in paraffin embedded samples. 
However, miRNAs can also present as “circulating miRNA” and be found in a variety 
of human body fluids such as urine, saliva, amniotic fluid and pleural fluid [5-9]. Since 
the first detection of circulating placenta-specific miRNAs in plasma reported by Chim 
et al. in 2008 [10], numerous studies have investigated miRNAs in blood samples. In 
2012 Russo et al. presented a database called miRandola [11]. This collated 
information from 89 studies, and contained 2132 entries with 581 circulating miRNAs 
identified in 21 sample types. 
 
It has been shown that circulating miRNAs present tissue-specific, reproducible and 
consistent expression among individuals in the same species [5], derive potentially 
directly from tumor tissue, thereby possibly correlating with tumor progression and 
recurrence [12,13], are highly stable in the circulation due to RNA binding proteins 
[14-17] or sub-cellular particles such as microvesicles or exosomes [17-20] and are 
resistant to unfavourable physiological conditions such as repeated freeze-thawing 
cycles or low / high pH [12,21]. Moreover, Weber et al. examined the expression of 
miRNAs in plasma, saliva, tears, urine, amniotic fluid, colostrum, breast milk, 
bronchial lavage, cerebrospinal fluid, peritoneal fluid, pleural fluid, and seminal fluid 
from normal individuals and found miR-335, miR-509-5p, miR-515-3p, miR-873 and 
miR-616 to be among the most abundant miRNAs present in all or most of the fluid 
types. Several of the highly abundant miRNAs in these fluids were common among 
multiple fluid types, however some of the miRNAs were enriched in specific fluids. 
The authors concluded that fluid type-specific miRNAs may have functional roles 
associated with the surrounding tissues [6]. Pigati et al. reported that the release of 
miRNAs into blood, milk and ductal fluids is selective and differs between normal and 
malignant mammary epithelial cells implicating a potential correlation of miRNA 
release and malignancy [22]. It therefore seems very likely, that circulating miRNAs 
might be valuable biomarkers for cancer diagnostics and prognostic evaluation. This 
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paper summarises the origin of circulating miRNAs, their stability in blood samples, 
and techniques to isolate exosomal miRNAs. It also highlights potential clinical 
applications for circulating miRNAs as biomarkers for diagnostic and prognostic 
evaluation. In particular this review focuses on applications relevant to 
gastrointestinal malignancies. Of the 15 most frequent malignancies worldwide, 5 are 
cancers of the gastro-intestinal tract (colorectum, stomach, liver, oesophagus, 
pancreas), and circulating microRNAs show potential as clinically relevant 
biomarkers in these cancers.  
 
 
Circulating miRNAs in blood samples 
 
Origin of circulating miRNAs 
 
There is increasing evidence that circulating miRNAs can be detected in blood 
samples from healthy individuals and patients with cancer, and several different 
mechanisms of origin for these circulating miRNAs have been established recently. 
Circulating miRNAs can originate from 1) active secretion via microversicles (MV) 
including exosomes [23-25], 2) active secretion in a protein / miRNA complex 
[15,24,25], 3) circulating miRNAs originating from blood cells such as immunocytes 
[25], and 4) passive secretion by tumor apoptosis and necrosis [24-26]. 
Consequently, when actively secreted, circulating miRNAs can indicate certain 
characteristics of the underlying tumor such as metastatic potential [27-29] or chemo-
sensitivity [30-33]. Furthermore, when passively secreted, they might be used as 
biomarkers of cell destruction, for example, in the context of myocardial infarction 
[26,34] or liver cirrhosis [35]. Figure 1 presents an overview about different origins of 
circulating miRNAs. 
 
Circulating exosomal miRNA 
 
Cells can release three types of vesicles: apoptotic bodies (500 nm – 3 um in 
diameter; released by cells undergoing apoptosis), microvesicles (100 nm – 1 um in 
diameter; released directly via plasma budding) and nanovesicles including 
exosomes (30 nm – 100 nm respectively 40 - 100 nm in diameter; released by 
exocytosis from endosome multivesicular bodies) [36,37]. Exosomes were first 
discovered in the 1970s [38]. After initial “mis-interpretation” as cell debris [39], 
exosomes were found in recent years to play a key role in cell transport, immune 
function and cancer. Exosomes are released into the extracellular environment via 
fusion of multivesicular bodies (MVB) with the plasma membrane [40]. Many cells, 
including reticulocytes, dendritic cells, B and T cells, mast cells, epithelial cells and 
tumor cells have the capacity to release exosomes [40]. Exosomes are present in 
nearly all body fluids [41] such as blood [42], urine [43], ascites [44], amniotic fluid 
[41] and saliva [45]. Exosomes share a lot of common (structural, adhesion and 
transportation) proteins, but they also contain cell-specific proteins such as major 
histocompatibility complex (MHC) class II or intestinal A33 when derived from B 
lymphocytes respectively colorectal cancer cells [46-48]. Valadi et al. demonstrated 
that exosomes carry mRNA and miRNA when released from mast cells. Interestingly, 
many of these RNA species seem to be specifically packaged exclusively into 
exosomes. Additionally, the mRNAs in the exosomes are translatable and encode 
proteins that are often exosome specific [40,49,50]. However, exosomal RNA profiles 
also differ between exosomes from different parental cells [51,52] and tumor-derived 
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exosomes may contain some “tumor specific” or “tumor enriched” miRNAs [42]. The 
release of exosomes might be regulated by tumor suppressor- or onco-genes, as 
exosomes are found more abundantly in the blood stream of patients with cancer 
compared to healthy individuals [42,53]. In addition, release of exosomes appears to 
be regulated by a ceramide-dependent secretory machinery [23]. 
 
Circulating miRNA / protein complex 
 
Turchinovich et al. investigated miRNA expression in plasma samples from healthy 
controls, and showed that expression of miR-16, miR-21 and miR-24 did not differ 
significantly in the samples, compared to the results obtained by simply centrifuging 
and filtering (0.22 μm filters) samples (i.e. with exosomes) with ultracentrifugated 
samples (i.e. without exosomes). They concluded that > 97% of the miRNA amount 
was “exosome free”. These extracellular miRNAs were demonstrated to bind to 
Argonaute (AGO) proteins (AGO2 in particular - a part of the RNA-inducing silencing 
complex), and to be extremely stable. The authors suggested that some miRNA / 
AGO2 complexes might be directly released by cells either as a by-product of cell 
death, or in a paracrine manner [15]. Another study investigating all four Argonaute 
proteins showed that only 14 out of 43 miRNAs presented similar binding patterns to 
either AGO1 or AGO2 in blood plasma, and that AGO-specific miRNA profiles in 
blood cells were markedly different from those in plasma. From these findings, the 
authors concluded that many cell types contribute to circulating miRNA and the 
majority of these are likely to be non-blood cells [16]. Other researchers 
demonstrated that high-density lipoproteins (HDL) and low-density lipoproteins (LDL), 
both involved in the transport of triglycerides and cholesterol, have the capability to 
carry miRNAs in their core [54,55].  
 
Circulating miRNAs originating from blood cells 
 
Recent studies revealed that, at least in part, cell-free circulating miRNAs could 
originate from blood cells [16,56,57]. Pritchard et al. compared the expression of 10 
miRNAs in plasma with blood cell counts. MiRNA expression presented cell type and 
cell count specific patterns for red blood cells (miR-451, miR-92a, miR-16, and miR-
486-5p) and myeloid blood cells (miR-223, let-7a, miR-197, and miR-574-3p; 
Pritchard 2012). However, this has to be considered in the context of blood cell 
derived miRNAs, as expression of miRNAs such as miR-16 and miR-451 can be 
affected by hemolysis [16,56-58]. The contribution of blood cells to cell-free 
circulating miRNAs has been raised as a consideration in related cancer biomarker 
studies, and it has been suggested that some reported circulating cancer associated 
miRNAs might be due to a secondary effect on blood cells, and not originate from 
tumor cells. 
 
Stability of circulating miRNAs  
 
Circulating miRNAs are protected from endogenous RNase activity by either being 
bound to proteins or by being packed into microparticles such as exosomes or 
microvesicles [17]. Li et al. analysed the expression of selected miRNAs (miR-16, 
miR-223, miR-30a, miR-320b, let-7b, miR-92a, miR-423-5p and miR-21) [14] and 
demonstrated that the vesicular structure of microvesicles provides general 
protection for stored miRNAs in healthy individuals. In addition, Tayler et al. 
investigated the stability of exosomal miRNAs under various storage conditions 
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(short time storage up to 96 h at 4C versus long time storage up to 28 days at -70C), 
and they found no significant differences in the stability of miRNAs between these 
groups [42]. Finally, Köberle and co-workers compared the stability of miRNAs 
packed in microvesicles versus those bound to proteins after incubation with RNase 
A or RNase inhibitor. They showed that vesicle-associated miRNAs appeared to be 
more stable and more resistant towards RNase A treatment compared to protein-
bound miRNAs [59].  
 
Techniques for isolation of exosomal miRNAs  
 
Today, various approaches have been established for the isolation of exosomal 
miRNAs. Of these, ultracentrifugation is by far the most widely accepted approach 
with potential for clinical application [60,93]. An alternative technique for miRNA 
isolation from exosomes is the immuno-isolation method. This uses magnetic beads 
coated with monoclonal antibodies (anti-HLA DP, DQ, DR) to couple exosomes 
through the proteins expressed on their surface [61,62]. A further way to isolate 
exosomal miRNAs is the use of the commercially available ExoQuick™ Kit.  
ExoQuick™ is a precipitation reagent that pellets exosomes simply by adding the 
reagent into pre-processed samples [63]. In addition a density gradient technique can 
also be used. For example, this is applied in the OptiPrepTM technique which 
separates vesicles based on the iodixanol gradient [65]. Finally, a fairly easy 
technique and potentially useful step for reducing contamination with non-exososmal 
miRNA in the context of exosome isolation protocols might be treatment of serum 
samples with RNase, as this might allow vesicle-associated (i.e. better protected 
from RNase treatment) and non-vesicle associated (i.e. less protected from RNAse 
treatment) miRNAs to be distinguished [59].  
 
All aforementined methods for exosome isolation have distinct advantages and 
disadvantages. Momen-Heravi and co-workers recently compared several of the 
isolation techniques for extracellular vesicles (EVs) including exosomes [93]. 
Ultracentrifugation for example, which is considered to be the current gold standard, 
is lengthy (4–5 h), requires an ultracentrifuge and recovers a relatively small 
proportion of the EVs. Furthermore, the sedimentation efficiency of EVs and 
sedimentation stability depend on the rotors being used, and viscosity also plays a 
role in the recovery of EVs [93]. On the other hand, immuno-isolation is a promising 
method for specific isolation and characterization of EVs and has been shown to be 
the most effective strategy for isolation of EVs when compared to differential 
centrifugation and density gradient separation, and this technique offers the 
advantage of flow cytometric, immune-blot, and electron microscopy analysis of 
bead-EVs complexes. However, this approach is not suited for large sample 
volumes, and captured EVs may not retain functionality [93].  
 
It has been shown previously that ExoQuick™ produces the largest amount and 
highest quality of exosomal RNA and proteins when compared to ultracentrifugation, 
immuno-isolation or size exclusion chromatography techniques. However, this 
technique isolates exosomes in general, and does not exhibit specificity for the 
originating cell [64,93]. Kalra et al. investigated the density gradient technique 
compared to two other EV isolation techniques (differential centrifugation coupled 
with ultracentrifugation and epithelial cell adhesion molecule immunoaffinity pull-
down), and showed that OptiPrepTM density gradient separation was superior to the 
two other approaches for isolating pure populations of exosomes [65]. Finally, 
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regarding the additional purification step of using RNAse treatment, this technique is 
the least expensive approach, easiest to perform, and can be performed using even 
smaller sample volumes [59]. However, it should be noted that surface proteins on 
vesicles can protect RNA from degradation, so in order for RNAse treatment to be 
effective it should be coupled with protease treatment [66]. 
 
General considerations about technical aspects of miRNA analysis in blood 
samples 
 
As outlined in a recent review by Moldovan and colleagues [92], developing 
circulating miRNA profiles as biomarkers is still in the early stages. There are many 
aspects that contribute to variability or potential inconsistency of research results, and 
these must be overcome before clinical translation can occur.  
 
With regards to sample acquisition and miRNA extraction, several issues have to be 
considered when planning experiments and interpreting data. It has been shown that 
factors such selection of the appropriate sample (e.g. plasma or serum), collection 
tubes (EDTA, citrate, heparin), extraction methods (phenol/chloroform, silica: distinct 
differences in required fluid volume, yield, procedural contaminants etc.), quality and 
quantity control, fasting or blood draw timing, all potentially impact on results of 
miRNA analyses in blood samples. 
 
With regards to miRNA profiling methods, there are a number of different technical 
approaches available, all of which present distinct advantages and disadvantages. 
These techniques include qRT-PCR, microarrays, sequence specific hybridization in 
solution followed by miRNA molecule counting based on reporter probes, and direct 
sequencing. While qRT-PCR approaches are fairly easy to perform and provide the 
best sensitivity and specificity in combination with very high absolute 
quantification/accuracy and flexibitiy, this technique is somewhat limited by its 
moderate to low throughput. Microarray techniqes provide very high throughput, but 
sensitivity / specificity / absolute quantification/accuracy and flexibitiy are lower 
compared to qRT-PCR approaches. In-solution hybridization yields moderate quality 
in all these mentioned aspects. 
 
The most promising technology for miRNA profiling might be the Next-Generation 
Sequencing, as it is the only technique that allows identification of novel miRNAs and 
is not limited to known miRNAs. In addition, this technique provides better specificity 
and flexibility (both very high) compared to microarray approaches, yields moderate 
sensitivity, but absolute quantification/accuracy. However, costs of this approach are 
very high, and significant computational infrastructure and bioinformatics support is 
required [92].  
 
Circulating miRNAs: a surrogate for underlying malignat diseases? 
 
Apart from the need to optimise and standardise methodology for circulating miRNA 
research, before clinical translation can be considered it is essential to confirm 
whether sensitive and specific circulating miRNAs profiles can be clearly linked to 
specific tumor types and tumor stages.  As a starting point towards this, it was first 
demonstrated that the amount of circulating EVs containing miRNA cargo is elevated 
in certain disease states, including various types of cancer [93,96]. However, since 
this time there is strong debate as to whether profiles of circulating miRNAs reflect 
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the expression pattern in the underlying tumors. Some authors have reported that 
circulating miRNAs in breast cancer or testicular germ cell tumor patients might not 
exhibit the same expression pattern as the underlying tumors [94,95]. However, 
others showed that the expression pattern of miRNAs in circulating exosomes in lung 
cancer and ovarian cancer patients for example were similar to the expression profile 
in the underlying tumor [96,97,99], or that selected miRNAs were generally lower 
expressed in microvesicles in glioma patients but correlated well with the tumor 
[98,99]. Chan and colleagues studied miRNA profiles in paired breast cancer tissue 
and serum samples, and suggested that their data might indicate selective release of 
miRNAs from breast cancer tissue into the blood stream [95]. Other studies have 
clearly demonstrated that specific miRNAs are selectively packaged into exosomes 
for export from tumor cells, and this results in a significant difference between the 
originating cancer cell miRNA profile compared to the cancer exosome miRNA profile 
[100,101]. Therefore it may not be reasonable to expect good concordance between 
tumor tissue miRNA profiles and tumor exosome miRNA profiles. Moreover, the issue 
of concordance between tissue and exosome miRNA profiles is probably less 
important than the question of whether miRNAs in the peripheral circulation correlate 
with tumor diagnosis and prognosis in cancer patients with sufficient sensitivity and 
specificity. This question will be examined in the following paragraphs.  
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Clinical applications of circulating miRNAs as diagnostic / prognostic 
biomarkers in cancer 
 
Given the fact that circulating miRNAs are on the one hand very stable in the 
peripheral blood stream, and on the other hand - even more importantly – mostly 
actively secreted into the blood, they might yield excellent biomarkers for cancer 
detection and prognosis. Hence, analysis of expression profiles of circulating 
miRNAs might provide a new tool for cancer diagnostics and screening, or for 
prognostic evaluation in individual patients.  
 
Circulating miRNAs as diagnostic markers 
 
Molecular biomarkers that detect cancer should exhibit significant and reproducible 
differences in expression between patients with cancer compared to healthy or other 
non-cancer controls. If these criteria are met, then these biomarkers might be useful 
for cancer screening, diagnosis or surveillance. A number of studies have analyzed 
expression profiles of circulating miRNAs in a variety of cancers, and investigated 
whether miRNA profiles differ between patients with compared to without cancer. 
There is increasing evidence demonstrating significant associations between the 
expression of certain miRNAs and different cancer types, highlighting their potential 
use as diagnostic biomarkers. 
 
For esophageal squamous cell carcinoma (ESCC), for example, Hirajima and co-
workers reported a significantly higher concentraton of miR-18a in plasma from 
patients with cancer, compared to healthy volunteers (sensitivity / specificity:  86.8% / 
100%; AUC = 0.9449) [30]. Another group examined selected miRNAs and showed 
that relative expression levels of circulating miR-155 and miR-183 were significantly 
reduced in patients with cancer, compared to controls. For miR-155, the authors 
determined an AUC of 0.66 [67]. A further study examining selected miRNAs 
revealed significantly higher plasma levels of miR-21 in patients with cancer 
compared to healthy volunteers, whereas the levels of miR-375 and miR-184 were 
significantly lower. In addition, the miR-21/miR-375 ratio was significant higher in 
patients with cancer, and the authors calculated an AUC value of 0.816 for miR-
21/miR-375 ratio. Interestingly, the authors found a reduction of miR-21 level after 
tumor removal. However, these results should be interpreted with caution as miR-184 
could not be detected in 50% of the patients with cancer due to its low expression 
[68]. Finally, Tanaka and colleagues showed that serum levels of miR-21, miR-145, 
miR-200c and let-7c were significantly higher in patients with cancer compared to 
healthy volunteers [69]. Sheinerman et al. compared miRNA expression pattern in 
plasma samples of patients with gastrointestinal diseases (including esophageal 
cancer, gastric cancer, colon cancer and Crohn’ s disease) and in patients with 
pulmonary diseases such as asthma, pneumonia and non-small cell lung cancer. By 
using pairs of specific miRNAs, the authors could distinguish between patients with 
gastrointestinal disease and healthy controls with an accuracy of 95% (miRNA pairs: 
miR-215/miR-30e-3p, miR-215/miR-145, miR-203/miR-30e-3p,  miR-203/miR-145) or 
patients with pulmonary disease with an accuracy of 94% (miRNA pairs: miR-
145/miR-155, miR-486-5p/miR-155, miR-145/miR-30e-3p, miR-192/miR-31). 
Unfortunately, the authors failed to provide details about the subtype of esophageal 
cancer included in this study [70].  
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In gastric cancer, several authors reported similar deregulation of circulating miRNAs 
in patients with cancer compared to healthy controls. Li et al., for example, 
demonstrated upregulation of miR-21 and miR-223, and downregulation of miR-218 
in patients with cancer compared to controls (miR-21: sensitivity / specificity: 74.29% 
/ 75.71%, AUC = 0.7432; miR-218: sensitivity / specificity: 94.29% / 44.29%, AUC = 
0.7432; miR-223: sensitivity / specificity: 84.29% / 88.57%, AUC = 0.9089) [71]. 
Another group confirmed significant miR-21 upregulation in patients with gastric 
cancer compared to other malignancies (sensitivity / specificity: 56.7% / 94.9 %, AUC 
= 0.81) [72]. Tsujiura et al. showed plasma concentrations of miR-17-5p, miR-106a, 
miR-106b and again of miR-21 to be significantly higher in patients with cancer 
compared to controls, whereas the levels of let-7a were significantly reduced. By 
using expression ratios between up- compared to downregulated miRNAs, the 
authors further demonstrated an improvement in sensitivity and specificity 
respectively in AUC (up to 0.879). Interestingly, the authors further investigated 
whether the miRNA deregulation observed in the plasma samples could also be seen 
in the miRNAs from the corresponding cancer tissue specimens. They showed that 
miR-106b presented a higher expression in primary gastric cancer tissue samples 
compared to adjacent normal mucosa from seven out of the eight patients (87.5%), 
whereas let-7a showed lower expression in seven of these patients. The authors 
concluded, that the miRNA levels from the primary cancer tissue and the plasma 
samples showed similar tendencies in most patients, and suggested that the levels of 
plasma miRNAs might reflect the expression level of the underlying tumor [73,74]. 
Zhu and collegueas recently published a detailed review and meta-analysis, which 
addressed deregulation of circulating miRNAs in patients with gastric cancer, and 
included 18 articles from 2010 to 2013. The review highlighted alterations in 
expression levels of miR-21, miR-27a and miR-106b, and emphasised that five cited 
studies reported upregulation of miR-21 in patients with cancer [74]. 
 
Regarding colorectal cancer, there have been only a few publications that address 
the potential for circulating miRNAs to be used for diagnosis in this cancer type. 
Giraldez et al., for example, performed a genome-wide profiling study of circulating 
miRNAs in a large number of plasma samples from patients with colorectal cancer, 
pre-malignant neoplastic lesions such as advanced adenomas and healthy controls. 
They found 6 miRNAs (miR-15b, miR-18a, miR-19a, miR-19b, miR-29a and miR-
335) were significantly upregulated in patients with cancer compared to controls 
(AUC between 0.80 and 0.70). Interestingly, in patients with colonic adenomas, only 
miR-18a was significantly upregulated (AUC = 0.64) [75]. Another study screened 
using microfluidic array technology the expression of 380 miRNAs in plasma samples 
from healthy controls compared to patients with adenomas or colorectal cancer. The 
authors showed that a panel of 8 miRNAs (namely miR-15b, miR-17, miR-142-3p, 
miR-195, miR-331, miR-532, miR-532-3p and miR-652) accurately identified patients 
with adenomas (AUC = 0.868). Furthermore, a 5-miRNA panel (miR-15b, miR-21, 
miR-142-3p, miR-331 and miR-339-3p) distinguished patients with advanced 
adenomas from patients with cancer (AUC = 0.856) [76]. 
 
For pancreatic cancer, again a fairly large body of evidence has confirmed 
deregulation of circulating miRNAs in blood samples from patients with cancer 
compared to controls. Morimura et al. demonstrated significant upregulation of miR-
18a levels in plasma from patients with pancreatic cancer compared to healthy 
controls (AUC = 0.9369) [77]. Further, Wang et al. reported upregulation of miR-21, 
miR-210, miR-155 and miR-196a in patients with ductal adenocarcinoma compared 
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to healthy controls (sensitivity / specificity for this panel: 64% / 89%; AUC 0.82) [78]. 
Similarly, Ho and co-workers showed a four-fold upregulation of miR-210 (normalized 
to miR-54) in plasma samples from patients with pancreatic cancer compared to 
controls [79]. Another study investigated miRNA expression in serum from patients 
with ductal adenocarcinoma, chronic pancreatitis and healthy controls. They 
investigated the expression of selected 7 miRNAs (miR-21, miR-155, miR-181a, miR-
181b, miR-196a, miR-221 and miR-222), which were validated in previous studies 
and shown to be highly expressed in pancreatic ductal adenocarcinoma tissue. 
Interestingly, upregulation of miR-21 distinguished patients with cancer from healthy 
controls or patients with pancreatitis, whereas miR-155 and miR-196a were 
upregulated in patients with either cancer or pancreatitis compared to healthy 
controls [80]. Liu et al. demonstrated upregulation of miR-26 and miR-196a in 
patients with cancer compared to controls. Furthermore, these authors showed that a 
combination of miR-26, miR-196a and the standard tumor marker CA 19-9 achieved 
an extraordinarily high sensitivity and specificity of 92.0% respectively 95.6% (AUC = 
0.979) for cancer compared to controls [81]. Another research group reported that 
the expression of a panel of 7 miRNAs (miR-20a, miR-21, miR-24, miR-25, miR-99a, 
miR-185 and miR-191) was significantly upregulated in patients with ductal 
adenocarcinoma compared to controls (accuracy 86.8%, AUC = 0.993). Most 
interestingly, the accuracy of this panel was far better than established tumor 
markers such as CA 19-9 and CEA [82]. Furthermore, Li et al. detected significantly 
elevated levels of miR-1290 in patients with pancreatic cancer in comparison to 
healthy controls or patients with chronic pancreatitis (AUC = 0.72), patients with 
pancreatic neuroendocrine tumors, and patients with intraductal papillary mucinous 
neoplasm (AUC = 0.76) [83].  
 
For hepatocellular carcinoma (HCC), a number of studies reported as well 
deregulations of circulating miRNAs to correlate to tumors. Shen et al., for example, 
found in a first set of plasma samples from patients with HCC compared to healthy 
controls seven miRNAs (miR-19b-1, miR-24, miR-29c, miR-92a, miR-376a, miR-378 
and miR-520c-3p) to be significantly differentially expressed in patients with cancer. 
A validation cohort confirmed only miR-483-5p to be associated with increased risk of 
hepatocellular carcinoma (sensitivity / specificity: 55.1% / 85.7%) [84]. Luo and co-
workers found miR-122a levels were significantly lower in serum samples from 
patients with HCC compared to controls (sensitivity / specificity: 70.6% / 67.1%; AUC 
= 0.707). In combination with Alpha-Feto-Protein (AFP), the detection rate of HCC 
could be improved further (sensitivity / specificity: 87.1% / 98.8%) [85]. However, 
these data have to be interpreted with caution as miR-122a might also be involved in 
viral replication in hepatitic C (HCV)- and hepatitis B (HBC)-related liver cancer 
[86,87].  In addition, another study reported that five plasma miRNAs (miR-23a, miR-
23b, miR-342-3p, miR-375 and miR-423,) were upregulated in HBV-related HCC 
patients, thereby providing a diagnostic miRNA signature to discriminate HBV-related 
HCC from controls (sensitivity / specificity: 99.9% / 99.4%; AUC = 0.999). 
Interestingly, the authors further reported a signature of four upregulated miRNAs 
(miR-10a, miR-223 miR-375 and miR-423), which differentiate patients with hepatitis 
B from healthy controls (sensitivity / specificity: 99.3% / 98.8%; AUC = 0.999) [88]. 
Finally, Li et al. found three miRNAs (miR-21, miR-222 and miR-224) were 
significantly overexpressed in serum samples of patients with HCC compared healthy 
volunteers [89].  
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To summarize, there is increasing evidence that levels of certain circulating miRNAs 
in patients with gastro-intestinal malignancies (Upper GI, Lower GI and Hepato-
Pancreato-Biliary) differ from those in healthy or non-malignant controls. Table 1 
summarise the data described above. This demonstrates the emerging potential for 
circulating miRNAs to be potent novel biomarkers for screening, diagnosis or 
surveillance of cancer.  
 
Circulating miRNAs as prognostic markers 
 
Another important aspect of clinical decision making for patients with cancer is the 
consideration of clinically relevant tumor characteristics, such as prognosis, 
metastatic potential or resistance towards conventional chemotherapies, and the 
abilty to reliably predict these opens the possibility of tailored or individualized cancer 
treatment. Molecular biomarkers that predict cancer prognosis need to present 
significant and reproducible expression differences between different prognosistic 
subgroups. For example, patients with locally advanced malignancy, lymph node 
involvement or metastases have a poorer prognosis, and if biomarkers could be used 
as surrogate markers that predict these factors and prognosis or likely success of 
treatment, then treatments might be tailored to the individual patient and tumor. 
Indeed, some recent early studies have addressed the question whether or not 
circulating miRNAs might be potential prognostic biomarkers in different cancer 
types. Whilst only a few studies have addressed this, initial evidence highlights the 
potential for these markers.  
 
For example, in esophageal squamous cell carcinoma (ESCC) expression levels of 
miR-18a in plasma have been shown to be significantly higher in patients with early 
stage tumors; i.e. pTis or stage I tumors [30]. nother research group has 
demonstrated a significantly increased risk for ESCC to be associated with reduced 
expression of circulating miR-155 and miR-183 (even after adjusting their data for 
potential confounders, such as smoking status and alcohol consumption; Liu 2012). 
Komatsu and co-workers found that patients ESCC and high plasma miR-21 levels 
showed a tendency to a shorter long term survival, while patients with elevated miR-
375 levels survived longer. Interestingly, patients with both high miR-21 and low miR-
375 levels, had a significantly worse prognosis than patients with the opposite 
expression pattern for these miRNAs (3-year survival rate: 48.4 versus 83.1%). 
Multivariate analysis confirmed the combination of high miR-21 and low miR-375 
levels in plasma to be an independent prognostic factor (hazard ratio 3.8 [1.14-12.5]) 
[68]. Currently, only one study has investigated the potential for circulating serum 
miRNAs to predict treatment response in ESCC. Tanaka et al. found that low levels 
of miR-200c correlated with a good clinical response to 5-fluorouracil (5-FU) and 
cisplatin plus adriamycin chemotherapy regimens (evaluated via computer 
tomography, endoscopy and PET/CT) but not with a 5-FU and cisplatin plus 
docetaxel regimen (p = 0.7167). High expression of miR-200c was also associated 
with shortened progression-free survival. The authors found no significant 
relationship between expression levels of miR-200c in pretreatment biopsies of the 
primary tumor and response to chemotherapy [69].  
 
In gastric cancer, Zheng and co-workers demonstrated a significant association 
between elevated miR-21 levels and increasing TNM stage and tumor size (AUC = 
up to 0.853) [90]. And Zhu et al. evaluated in their aforementioned meta-analysis the 
prognostic value of circulating miRNAs, and found that elevated levels of circulating 
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miR-17-5p, miR-20a, miR-21 and miR-200c were significantly correlated with overall 
survival, and predicted poor prognosis [74].  
 
For patients with colorectal cancer, similar deregulations of certain miRNAs in 
different outcome-relevant subgroups have been described. Toiyama et al. identified 
miR-200c as the serum miRNA being best associated with metastasis. These 
authors found significantly higher serum miR-200c levels with stage IV cancer 
compared to stage I-III, and high expression miR-200c was also significantly 
associated with lymph node metastasis, liver metastasis and the development of 
distant metastases. High miR-200c levels, furthermore, represented an independent 
predictor of lymph node metastasis in these patients [hazard ratio = 4.81, 95% 
confidence interval = 1.98–11.7) [27]. Another two studies investigated the potential 
for circulating miRNAs to predict treatment response: Zhang et al. used TaqMan low-
density arrays to screen miRNA expression in serum from a large patient cohort that 
underwent chemotherapy and compared the expression pattern to treatment 
response. They found 17 serum miRNAs correlated with chemosensitivity, and finally 
selected a panel of five miRNAs (miR-20a, miR-130, miR-145, miR-216 and miR-
372), which were significantly downregulated in the responder group. This panel 
reached an AUC of up to 0.918 for its ability to distinguish between responders and 
non-responders (AUC for CEA = 0.689 and CA19-9 =0.746) [31]. Finally, another 
research group compared the expression of 742 miRNAs in plasma samples from 
cancer patients before commencement and after four cycles of 5-FU/oxaliplatin 
chemotherapy. They identified three miRNAs (miR-106a, miR-130b and miR-484), 
which were significantly upregulated before treatment in non-responders. Moreover, 
high expression of miR-27b, miR-148a, and miR-326 was associated with decreased 
progression-free survival, and high miR-326 expression correlated with decreased 
overall survival (HR 1.5, 95% CI 1.1-2.0) [32]. 
 
In patients with pancreatic cancer high levels of miR-196a in serum have been found 
to be significantly associated with unresectable disease, the TNM staging and 
median survival (high versus low expression of miR-196a: median survival of 6.1 
months versus 12 months [80]. Similarily, another research group reported a panel of 
7 upregulated miRNAs (miR-20a, miR-21, miR-24, miR-25, miR-99a, miR-185 and 
miR-191), which improved the detection of early stage pancreatic cancer, compared 
to CA 19-9 or CEA (detection rate of 46.2% / 62.5% respectively 30.8% / 62.5% in 
stage I / stage II cancer). Furthermore, patients with high levels of miR-21 had poorer 
survival [82]. In addition, Wang et al. demonstrated, that elevated serum miR-21 
levels were independent prognostic factors for both, lower time-to-progression and 
overall survival. As miR-21 expression in cancer tissue has been reported to be 
associated with clinical outcome and the success of gemcitabine treatment in 
patients with pancreatic cancer, the authors suggested that miR-21 serum levels 
might serve as potential predictors of chemosensitivity [91]. Finally, serum miR-1290 
levels have been shown to distinguish between patients with early-stage pancreatic 
cancer compared to controls better than CA19-9 levels, and miR-1290 has been 
identified to be independent predictor of pancreatic cancer prognosis [83].  
 
For hepatocellular carcinoma (HCC), comparable results have been published with 
correlations between the expression of circulating miRNAs and factors affecting 
outcome also reported. Koeberle et al., for example, compared selected serum 
miRNA levels in patients with HCC compared to liver cirrhosis. While serum miR-1 
and miR-122 levels did not differ significantly between patients with cancer compared 
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to liver cirrhosis without HCC, the authors found that patients with HCC with higher 
miR-1 and miR-122 serum levels survived longer than individuals with low 
expression. Furthermore, the authors demonstrated miR-1 serum levels to be 
independently associated with overall survival. Serum miR-122 levels correlated 
negatively with MELD score, supporting the hypothesis that patients with high miR-
122 serum levels do have a better liver function and survive longer [59].  In addition, 
Luo et al. found miRNA-122a expression to be significantly lower in males, and there 
was a trend towards lower expression in patients who smoked cigarettes, consumed 
alcohol, had a family history of HCC or were positive for Hepatitis B virus infection. Li 
and colleagues showed that high levels of miR-221 correlated significantly with 
existence of cirrhosis, tumor size and tumor stage in patients with HCC. In addition, 
these authors reported a trend towards increased miR-221 expression with 
progression of TNM stage (stage I < stage II < stage III–IV) [89]. 
 
These initial results suggest that circulating miRNAs in patients with cancer might be 
useful new biomarkers which might aid assessment of prognosis, response to 
treatment and outcome in gastro-intestinal malignant tumors in the Upper and Lower 
GI tract, and also in Hepato-Pancreato-Biliary tumors. Table 2 summarises the data 





Since the first reported discovery of miRNAs several years ago, it has become very 
clear that these components of the epigenetic machinery play a key role in cancer 
initiation, development and progression. In 2008 came the first report of miRNAs 
detection in peripheral blood samples. Since then, a number of research groups 
examined these so called “circulating miRNAs”, and found that there are different 
types of origin for these molecules in the blood stream, and that these circulating 
miRNAs are quite stable in the circulation. These characteristics suggest that 
circulating miRNAs might be useful blood-based biomarkers in patients with cancer. 
In this context, two aspects are of particular interest for the clinician: on the one 
hand, ideal biomarkers should present significant and reproducible differences in 
expression between patients with compared to without cancer in order to allow their 
use for screeing purposes, diagostics and surveillance of cancer. On the other hand, 
molecular biomarkers that impact on prognosis should present significant and 
reproducible differences in expression between different patient subgroups, thereby 
contributing to the prognostic assessment of patients with cancer. The early data 
available for gasto-intestinal malignant tumors demonstrates a promising picture. A 
large number of miRNAs have been reported to show different expression patterns 
between patients with cancer compared to controls, and between subgroups of 
patients with better compared to worse prognosis. A number of these miRNA 
candidates have been detected in more than just one study, and their expression 
also correlates with the presence of tumors or cancer prognosis in different tumor 
types, highlighting their multi-facted potential clinical utility in cancer. Table 3 
presents in this context an overview about the most promising circulating miRNA 
candidates for diagnostic or prognostic evaluation.  
 
However, it is still to early to determine whether circulating miRNAs will influence 
daily clinical practice and decision making in the future. Data so far have been 
derived from early studies that have several limitations. Most of these studies have 
included only small groups of patients, and there have been no prospective 
evaluations of circulating miRNAs as potential biomarkers reported so far. 
Furthermore, there are a wide range of experimental techniques currently in use for 
the assessment of circulating miRNAs, and no standardisation of approach to this 
area. As all of these approaches (including sample aquisation, preparation, isolation 
of miRNAs or EVs, miRNA profiling and interpretation of data amongst others) are 
varied, a definitive comparison of the results of different studies is not possible. 
Moreover, the question about the origin of circulating miRNAs yet to be fully 
answered, although this will impact on our understanding of biological aspects of 
tumor initiation and progression, and the meaning of circulating miRNAs in the 
context of cell-to-cell interactions. Finally, as this review has focussed on cancers of 
the gastro-intestinal tract, caution should be applied when extrapolating to other 
cancer types. Each tumor type (or even subtype) will need to be evaluated 
separately, if circulating miRNAs are to be defined as a new source of molecular 
biomarkers in the respective cancers. These considerations clearly show that further 
research efforts is required to definitively establish circulating miRNAs as clinically 
useful biomarkers that will impact on the assessment and treatment of patients in the 
clinical setting.  
 
However, despite the early stage of research on circulating miRNAs to date, the 
initial data in this field appear positive, and support the contention that circulating 
 16 
miRNAs have great potential to improve diagnostic and prognostic evaluation in 
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FIGURE 1. Different sources of circulating miRNAs 
In the cell nucleus, primary miRNAS (pri-miRNAs) were transcripted and cleaved by 
the microprocessor complex Drosha/DGCR8 into shorter miRNA precursors (pre-
miRNA), and finally transported in the cytoplasm. Mature miRNAs were then 
released via different ways into the circulation: 
 
A. Released in microvesicles after for example fusion of multivesicular bodies 
(MVBs) with the plasma membrane (exosomes) or the release by endocytic 
membrane transport pathway (endosomes) 
B. Released in a miRNA-protein complex, as for example bound to Ago2, HDL 
and LDL. 
C. Encapsulated into apoptotic bodies by (tumor) apoptosis and tumor necrosis 






TABLE 1. Circulating miRNA as diagnostic marker  
The table presents an overview about deregulations of specific miRNAs in gasto-
intestinal malignant tumors from the Upper to the Lower GI tract including Hepato-
Pancreato-Biliary tumors, compared to healthy or non-malignant controls. ESCC = 
esophageal squamous cell carcinoma, CA = cancer, GA = gastric cancer, CP = 
chronic pancreatitis, IPMN = intraductal papillary mucinous neoplasms, BPD = 
benign pancreatic disease, HBV-rel. = HBV related. 
 
TABLE 2. Circulating miRNA as prognostic marker  
The table presents an overview about deregulations of specific miRNAs in prognostic 
relevant subgroups of patients with gasto-intestinal malignant tumors from the Upper 
to the Lower GI tract including Hepato-Pancreato-Biliary tumors. ESCC = esophageal 
squamous cell carcinoma, CTX=chemotherapy. 
 
TABLE 3. Most promising circulating miRNA candidates for diagnostic or 
prognostic evaluation 
The table presents a selection of circulating microRNAs that were found in more than 
one study to be deregulated between cancer patients and controls (diagnostic) or 
between different prognostic relevant subgroups of cancer patients (prognostic). In 
total, 46 miRNAs were described in more than one study to be deregulated. 
However, we selected  miRNAs that were named more than once.  
Red cell: up-regulation of miRNA; green cell: down-regulation of miRNA.  
ESCC = esophageal squamous cell carcinoma, CA = cancer, miR-19 family: includes 
miRNA19a and miRNA19b; miR-29 family includes miRNA29a and miRNA-29c; miR-
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